Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 46

1.

Targeted immunotherapy for non-small cell lung cancer.

Vasekar M, Liu X, Zheng H, Belani CP.

World J Clin Oncol. 2014 May 10;5(2):39-47. doi: 10.5306/wjco.v5.i2.39. Review.

PMID:
24829850
[PubMed]
Free PMC Article
2.

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.

Iannone R, Miele L, Maiolino P, Pinto A, Morello S.

Am J Cancer Res. 2014 Mar 1;4(2):172-81. eCollection 2014.

PMID:
24660106
[PubMed]
Free PMC Article
3.

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.

Sondel PM, Gillies SD.

Antibodies (Basel). 2012 Jul 4;1(2):149-171.

PMID:
24634778
[PubMed]
Free PMC Article
4.

Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".

Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G.

Toxins (Basel). 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914.

PMID:
24594636
[PubMed - in process]
Free PMC Article
5.

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M.

J Exp Clin Cancer Res. 2013 Oct 25;32:82. doi: 10.1186/1756-9966-32-82.

PMID:
24423086
[PubMed - in process]
Free PMC Article
6.

Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.

Baldo BA.

Oncoimmunology. 2013 Oct 1;2(10):e26333. Epub 2013 Oct 17. Review.

PMID:
24251081
[PubMed]
Free PMC Article
7.

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.

Jure-Kunkel M, Masters G, Girit E, Dito G, Lee F, Hunt JT, Humphrey R.

Cancer Immunol Immunother. 2013 Sep;62(9):1533-45. doi: 10.1007/s00262-013-1451-5. Epub 2013 Jul 20.

PMID:
23873089
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Evolving pharmacotherapies for the treatment of metastatic melanoma.

Salama AK.

Clin Med Insights Oncol. 2013 Jun 20;7:137-49. doi: 10.4137/CMO.S9565. Print 2013.

PMID:
23843723
[PubMed]
Free PMC Article
9.

Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.

Weber J, Hamid O, Amin A, O'Day S, Masson E, Goldberg SM, Williams D, Parker SM, Chasalow SD, Alaparthy S, Wolchok JD.

Cancer Immun. 2013 May 1;13:7. Print 2013.

PMID:
23833564
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Ipilimumab and its toxicities: a multidisciplinary approach.

Fecher LA, Agarwala SS, Hodi FS, Weber JS.

Oncologist. 2013 Jun;18(6):733-43. doi: 10.1634/theoncologist.2012-0483. Epub 2013 Jun 17. Review.

PMID:
23774827
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.

Luke JJ, Hodi FS.

Oncologist. 2013 Jun;18(6):717-25. doi: 10.1634/theoncologist.2012-0391. Epub 2013 May 24. Review.

PMID:
23709751
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Wolchok JD, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Cykowski L, de Pril V, Humphrey R, Lebbé C.

Ann Oncol. 2013 Aug;24(8):2174-80. doi: 10.1093/annonc/mdt161. Epub 2013 May 10.

PMID:
23666915
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.

Zielinski C, Knapp S, Mascaux C, Hirsch F.

Ann Oncol. 2013 May;24(5):1170-9. doi: 10.1093/annonc/mds647. Epub 2013 Feb 7. Review.

PMID:
23393121
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.

Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A.

Clin Med Insights Oncol. 2013;7:1-12. doi: 10.4137/CMO.S7256. Epub 2012 Dec 20.

PMID:
23362372
[PubMed]
Free PMC Article
15.

The evolution of S100B inhibitors for the treatment of malignant melanoma.

Hartman KG, McKnight LE, Liriano MA, Weber DJ.

Future Med Chem. 2013 Jan;5(1):97-109. doi: 10.4155/fmc.12.191. Review.

PMID:
23256816
[PubMed - indexed for MEDLINE]
Free PMC Article
16.
17.

In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer.

Guo C, Yi H, Yu X, Zuo D, Qian J, Yang G, Foster BA, Subjeck JR, Sun X, Mikkelsen RB, Fisher PB, Wang XY.

Mol Cancer Ther. 2012 Nov;11(11):2331-41. doi: 10.1158/1535-7163.MCT-12-0164. Epub 2012 Aug 15.

PMID:
22896667
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Biomarkers on melanoma patient T cells associated with ipilimumab treatment.

Wang W, Yu D, Sarnaik AA, Yu B, Hall M, Morelli D, Zhang Y, Zhao X, Weber JS.

J Transl Med. 2012 Jul 12;10:146. doi: 10.1186/1479-5876-10-146.

PMID:
22788688
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Novel therapeutic approaches for small cell lung cancer: the future has arrived.

Pietanza MC, Rudin CM.

Curr Probl Cancer. 2012 May-Jun;36(3):156-73. doi: 10.1016/j.currproblcancer.2012.03.005. Epub 2012 Apr 10. No abstract available.

PMID:
22495056
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma.

Kleiner DE, Berman D.

Dig Dis Sci. 2012 Aug;57(8):2233-40. doi: 10.1007/s10620-012-2140-5. Epub 2012 Mar 21. No abstract available.

PMID:
22434096
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk